3 October 2018 - - US-based biopharmaceutical company Kala Pharmaceuticals, Inc. (NASDAQ: KALA) has commenced an underwritten public offering of 7.5m shares of its common stock, the company said.

Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1.125m shares of common stock offered in the public offering at the public offering price, less the underwriting discount.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

J.P. Morgan, BofA Merrill Lynch and Jefferies will act as joint bookrunning managers for the offering. Cantor Fitzgerald and Co. is serving as lead manager for the offering, and Wedbush PacGrow and Oppenheimer and Co. Inc. are acting as co-managers for the offering.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary MPP technology, with an initial focus on the treatment of eye diseases.

The company has applied the MPP technology to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.